Mesoblast (MESO) Non-Current Debt (2018 - 2025)
Mesoblast (MESO) posted quarterly Non-Current Debt of -$149.3 million for Q4 2025, down 7.0% year-on-year from -$160.6 million in Q4 2024, and down 192.43% on a QoQ basis from $161.6 million in Q2 2025.
Mesoblast (MESO) Non-Current Debt (2018 - 2025) Analysis & Trends
Mesoblast (MESO) has reported Non-Current Debt for 8 consecutive years, with -$149.3 million the latest figure, recorded in Q4 2025.
- Quarterly Non-Current Debt fell 7.0% year-over-year to -$149.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$149.3 million (down 7.0% YoY) and the FY2025 annual result came in at $161.6 million, up 60.77% from the prior year.
- Non-Current Debt slipped to -$149.3 million in Q4 2025 per MESO's latest filing, from $161.6 million in the prior quarter.
- Over the last five years, Non-Current Debt for MESO reached as high as $161.6 million in Q2 2025 and fell as low as -$149.3 million in Q4 2025.
- A 5-year average of $13.5 million and a median of $42.7 million in 2021 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt soared 123.21% — and 2023, when it slumped 234.31%.
- Year by year, Non-Current Debt stood at $86.5 million in 2021, then sank by 233.71% to -$115.7 million in 2022, then declined by 6.29% to -$123.0 million in 2023, then decreased by 13.46% to -$139.5 million in 2024, then dropped by 7.0% to -$149.3 million in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered -$149.3 million, $161.6 million, and -$139.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | -149.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -149.32 Mn |
| Jun 30, 2025 | 161.55 Mn |
| Dec 31, 2024 | -139.55 Mn |
| Jun 30, 2024 | 100.48 Mn |
| Dec 31, 2023 | -122.99 Mn |
| Jun 30, 2023 | 102.81 Mn |
| Mar 31, 2023 | -119.06 Mn |
| Dec 31, 2022 | -115.72 Mn |
| Sep 30, 2022 | 94.19 Mn |
| Jun 30, 2022 | 91.62 Mn |
| Mar 31, 2022 | 88.65 Mn |
| Dec 31, 2021 | 86.54 Mn |
| Sep 30, 2021 | 42.65 Mn |
| Jun 30, 2021 | 41.05 Mn |
| Mar 31, 2021 | 39.85 Mn |
| Dec 31, 2020 | 49.09 Mn |
| Sep 30, 2020 | 56.10 Mn |
| Jun 30, 2020 | 57.02 Mn |
| Mar 31, 2020 | 59.95 Mn |
| Dec 31, 2019 | 66.00 Mn |